Federal Register #2026-09231

Licensing Opportunity: Novel T-Cell Immunotherapy Technology from NCI/NIH

The National Cancer Institute (NCI), part of the NIH, is seeking licensing partners for a novel T-cell immunotherapy technology targeting inhibitory transmembrane adapter proteins SIT1, LAX1, and TRA T1. - Government Buyer: - National Cancer Institute (NCI), NIH Technology Transfer Center - OEMs and Vendors: - No specific OEMs or commercial vendors are named; technology is developed by NCI/NIH - Products/Services Requested: - Therapeutic targeting of SIT1, LAX1, and TRA T1 proteins for T-cell immunotherapy - Part Number: E0042024 - Pre-clinical development stage - Potential applications: cancer, infectious diseases, autoimmune diseases - Licensing opportunity for further development and commercialization - Unique/Notable Requirements: - Technology is protected by a PCT patent application - Focus on enhancing T-cell cytotoxicity and overcoming immunosuppression - Opportunity is for licensing, not direct procurement - Place of Performance/Delivery: - NIH Rockledge II facility, Bethesda, MD - Additional Context: - NIH's Center for Scientific Review is conducting virtual grant review meetings (not a procurement opportunity) - No products or services are being procured for these meetings

Description

This notice announces closed meetings scheduled by the Center for Scientific Review, part of the National Institutes of Health under the Department of Health and Human Services. The meetings are set for June 9-10, 2026, and will be closed to the public due to the discussion of confidential trade secrets, commercial property, and personal information related to grant applications. The meetings will be conducted virtually and involve review and evaluation of grant applications across various scientific review groups and study sections. Contact information for scientific review officers is provided for each meeting.

View original listing